Cardiovascular risk and triptan usage among patients with migraine
This retrospective, population-based study found that triptan usage did not increase CV risk among patients with migraine, even in those with existing CV risk factors, where no formal contraindication exists. The study highlights the importance of considering individual risk factors when prescribing triptans, as certain subgroups may still be at higher risk.
Authors
- Yana Mechnik Steen
- Victor Novack (ORCID: https://orcid.org/0000-0001-8706-9622)
- Ran Abuhasira (ORCID: https://orcid.org/0000-0001-7031-6498)
- Eran Levanon (ORCID: https://orcid.org/0009-0002-1762-2343)
- Gal Ifergane
- Michal Gordon
- Ido Peles (ORCID: https://orcid.org/0000-0001-8772-1780)
- Ruth Smadar Shneyour
- Ibraheem Abu Salameh
Institutions
- Ben-Gurion University of the Negev (IL)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-06-22
- DOI
- https://doi.org/10.1111/head.14968
- Citations
- 8
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 11.77
Funders
- Pfizer